Literature DB >> 28917024

Decreased percentage of peripheral naïve T cells is independently associated with ischemic stroke in patients on hemodialysis.

Rongyi Chen1,2,3, Jiachang Hu1,2,3, Fangfang Xiang1,2,3, Xiao Tan1,2,3, Bo Shen1,2,3, Zhonghua Liu1,2,3, Wenlv Lv1,2,3, Xiaoqiang Ding1,2,3, Xuesen Cao4,5,6, Jianzhou Zou7,8,9.   

Abstract

PURPOSE: Cerebrovascular complications, including ischemic stroke, account for poor outcomes in patients on hemodialysis. T cell responses may be involved in the pathogenesis of ischemic stroke. We aimed to evaluate the role of naïve T cells in development of ischemic stroke in patients on hemodialysis.
METHODS: In this cross-sectional study, 156 patients on hemodialysis in our blood purification center were included. These patients were divided into the ischemic stroke (IS) group (61 cases) and non-ischemic stroke (non-IS) group (95 cases) according to a new diagnosis after initiation of hemodialysis. After being lysed with red blood cell lysis solution, peripheral blood was tested by flow cytometry to detect the expression of CD45RO and CCR7 in CD4 T and CD8 T cells. Correlation analysis and logistic regression analysis were conducted to identify potential independent risk factors for ischemic stroke.
RESULTS: The percentage of peripheral naïve T cells was lower in the IS group [median (interquartile range (IQR)) 13.9% (8.6-22.9%)] compared with the non-IS group [median (IQR) 22.7% (15.9-32.2%), P < 0.001]. Spearman correlation analysis showed that naïve T cells were negatively associated with ischemic stroke (r = -0.308, P < 0.001). Multivariate logistic regression analysis showed that CD4 naïve T cells had an independent negative association with ischemic stroke in patients on hemodialysis (odds ratio 0.933, 95% CI 0.883, 0.986; P = 0.013).
CONCLUSION: A decrease in percentage of peripheral CD4 naïve T cells is a risk factor for ischemic stroke in patients on hemodialysis.

Entities:  

Keywords:  Hemodialysis; Ischemic stroke; Naïve T cell; Sedative-hypnotic drug

Mesh:

Substances:

Year:  2017        PMID: 28917024     DOI: 10.1007/s11255-017-1691-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  33 in total

Review 1.  A killer on the road: circulating CD4(+)CD28null T cells as cardiovascular risk factor in ESRD patients.

Authors:  Michiel G H Betjes; Ruud W J Meijers; Lucia E A de Wit; Nicolle H R Litjens
Journal:  J Nephrol       Date:  2012 Mar-Apr       Impact factor: 3.902

2.  Plasma indoleamine 2,3-dioxygenase concentration is increased in hemodialysis patients and may contribute to the pathogenesis of coronary heart disease.

Authors:  Theodoros Eleftheriadis; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis; Grammati Galaktidou
Journal:  Ren Fail       Date:  2011-10-21       Impact factor: 2.606

3.  Naïve and central memory T-cell lymphopenia in end-stage renal disease.

Authors:  J-W Yoon; S Gollapudi; M V Pahl; N D Vaziri
Journal:  Kidney Int       Date:  2006-05-31       Impact factor: 10.612

4.  Mortality rate of patients with end stage renal disease on regular hemodialysis: a single center study.

Authors:  Mohamed Elhafiz Elsharif
Journal:  Saudi J Kidney Dis Transpl       Date:  2011-05

5.  Plasma indoleamine 2,3-dioxygenase and arginase type I may contribute to decreased blood T-cell count in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Efi Yiannaki; Georgia Antoniadi; Vassilios Liakopoulos; Georgios Pissas; Grammati Galaktidou; Ioannis Stefanidis
Journal:  Ren Fail       Date:  2012-08-17       Impact factor: 2.606

6.  Premature aging of circulating T cells in patients with end-stage renal disease.

Authors:  Michiel G H Betjes; Anton W Langerak; Ashley van der Spek; Elly A de Wit; Nicolle H R Litjens
Journal:  Kidney Int       Date:  2011-04-27       Impact factor: 10.612

7.  Prevalence of circulating CD4+CD28null T cells is associated with early atherosclerotic damage in patients with end-stage renal disease undergoing hemodialysis.

Authors:  Zhiping Sun; Hong Ye; Bing Tang; Xia Shen; Xiaochun Wu; Hua Zhong; Weizong Song
Journal:  Hum Immunol       Date:  2012-08-16       Impact factor: 2.850

Review 8.  Immune cell dysfunction and inflammation in end-stage renal disease.

Authors:  Michiel G H Betjes
Journal:  Nat Rev Nephrol       Date:  2013-03-19       Impact factor: 28.314

9.  Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis.

Authors:  Mark D Findlay; Peter C Thomson; Rachael L Fulton; Marit D Solbu; Alan G Jardine; Rajan K Patel; Kathryn K Stevens; Colin C Geddes; Jesse Dawson; Patrick B Mark
Journal:  Stroke       Date:  2015-07-30       Impact factor: 7.914

10.  Factors associated with the elevated percentage of CD4CD69 T cells in maintained hemodialysis patients.

Authors:  Rongyi Chen; Fangfang Xiang; Jiachang Hu; Xuesen Cao; Xiao Tan; Ping Jia; Ting Zhang; Nana Song; Yi Fang; Xiaoqiang Ding; Jianzhou Zou
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

View more
  1 in total

1.  Evaluation of monocyte-to-high-density lipoprotein cholesterol ratio and monocyte-to-lymphocyte ratio in ischemic stroke.

Authors:  Huiling Liu; Feng Zhan; Yazhou Wang
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.